Recent developments in prostate cancer biomarker research: therapeutic implications

被引：19
作者：
Detchokul, Sujitra [1 ]
Frauman, Albert G. [1 ]
机构：
[1] Univ Melbourne, Dept Med Austin Hlth No Hlth, Clin Pharmacol & Therapeut Unit, Heidelberg, Vic 3084, Australia
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 71卷 / 02期
关键词：
biomarker; prostate cancer; review; PHASE-I TRIAL; GROWTH-FACTOR-RECEPTOR; HISTONE DEACETYLASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID; P53 PROTEIN ACCUMULATION; MEMBRANE ANTIGEN; CELLULAR IMMUNOTHERAPY; IMATINIB MESYLATE; MAMMALIAN TARGET; CLINICAL-TRIAL;
D O I：
10.1111/j.1365-2125.2010.03766.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
This review aims to present an overview of recent clinical trials targeting biomarkers in advanced prostate cancer. We searched ClinicalTrials.gov for early phase clinical trials on treatments of prostate cancer that have been recently completed, are ongoing or are actively recruiting participants. Drug targets and their mechanism of actions were assessed and summarized. Trials were categorized according to prostate cancer biomarkers that have potential as therapeutic targets. A total of 19 new therapeutic agents for the treatment of prostate cancer are included in this review. Trials are summarized according to the targeted biomarkers and are categorized into five therapeutic approaches: prostate cancer vaccine, epigenetic therapy, pro-apoptotic agents, prostate cancer antibodies and anti-angiogenesis approach. Some of the therapeutic agents reviewed showed promising results, warranting further investigation in late phase clinical trials. Recent novel prostate cancer biomarkers that made it through clinical trials and their relevance as drug targets are summarized. This review emphasizes the importance of specific prostate cancer biomarkers and their potentials as targets of the disease. Some clinical trials of targeted treatments in prostate cancer show promising results. Better understanding of disease mechanisms should potentially lead to more specific treatments for individual patients.
引用
收藏
页码：157 / 174
页数：18
相关论文
共 167 条
[51]  
ClinicalTrials. gov, 2008, DOS FIND STUD IV PAN
[52]  
ClinicalTrials. gov, 2009, 177LU RAD MON ANT HU
[53]  
ClinicalTrials. gov, 2003, MLN2704 SUBJ MET AND
[54]  
ClinicalTrials. gov, 2006, STUD OR PXD101 PAT A
[55]  
ClinicalTrials. gov, 2006, SUN MAL HORM ABL PAT
[56]  
ClinicalTrials. gov, 2004, DOC OBL TREAT PAT HO
[57]  
ClinicalTrials. gov, 2008, ANDR ABL THER VACC T
[58]  
ClinicalTrials. gov, 2007, RAD PROST CANC US 17
[59]  
ClinicalTrials. gov, 2005, STUD IM DOC PROST CA
[60]  
ClinicalTrials. gov, 2009, SINGL AG TEMS TOR R
12345678910